A combinational treatment, including immune checkpoint blockade and cancer vaccine, is also under evaluation, such as the above vaccine with a PD-L1 inhibitor, atezolizumab, for end-stage CRC cases characterized by MSS [138]. The gene discussed is CD274; the disease is cancer.